Biobank Sample Preparation Patents: Top Companies & Trends 2026
Biobank Sample Preparation Patents: Who Holds the Ground
74.8% of all 254 records sit with just five assignees, a concentration ratio that leaves little room for a new entrant to file broad claims in the core routes. Annual filings rose to a peak of 58 in 2023, then declined to 7 by 2024 — a 53% drop from the 15 filed in 2021. 2025 and 2026 figures are still incomplete due to publication lag and should not be read as a continued decline.
- 1VELICO MEDICAL INC77
- 2SYNCHRONICITY PHARMA INC37
- 3TRUSTEES OF TUFTS COLLEGE27
- 4EMERGENT BIODEFENSE OPERATIONS LANSING LLC26
- 5SEQUENOM INC23
See the full biobank sample preparation analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions
Who are the leading patent holders in biobank sample preparation?
The ranking covers 26 companies, and it is heavily concentrated: the top five hold 190 of 254 records in scope (74.8%), with the single leading assignee alone holding 77 records. Past the top ten, which together hold 90.6% of records, filings drop to single digits per company and then to isolated single filings. This means competitive attention should focus on the handful of leaders rather than the long tail.
Is patent filing in this field still growing?
No, filing activity has cooled since a peak of 58 records in 2023. Between 2021 and 2024, annual filings fell 53%, from 15 to 7. Because publications lag filing by roughly 18 months, the 2025-2026 figures are still incomplete and should not be read as confirming a further decline; they simply have not finished arriving yet.
What technology areas dominate the claims in this space?
Medicinal preparations (IPC class A61K) appear in 45.7% of the 254 records, making it the single largest technology class by a wide margin. Drying processes (F26B) and enzyme/DNA measurement methods (C12Q) each cover close to a quarter of records. Because a single patent can carry multiple IPC classes, these percentages overlap rather than summing to a whole.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Biobank Sample Preparation covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.